tbuckley/cabot-search huggingface dataset:
FRI0207 A phase I/II clinical trial of intra-articular administration of ARG098, an anti-FAS IGM monoclonal antibody, in knee joint synovitis of japanese patients with rheumatoid arthritis
Authors: T. Matsubara, K. Okuda, J. Chiba, A. Takayama, H. Inoue, T. Sakurai, H. Wakabayashi, A. Kaneko, K. Sugimoto, H. Yamazaki, T. Takanashi, Y. Takasaki, N. Tamura, M. Ogasawara, M. Inoo, I. Onishi, S. Kawai, R. Nohara
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> ARG098, a chimeric anti-Fas IgM monoclonal antibody, possesses a novel mode of action totally different from those of currently available RA therapeutics including cytokine targeting biologics. The Fas molecule (also known as APO-1 or CD95) mediates apoptosis in response to Fas ligand (Fas-L). Preclinical studies demonstrated that ARG098 specifically targets the Fas molecule leads to apoptosis in synoviocytes. <h3>Objectives</h3> An open-label sequential dose-escalation study of ARG098 was conducted to assess the safety and efficacy. <h3>Methods</h3> 43 patients diagnosed by the ACR criteria with knee joint synovitis were enrolled. The study had 7 dose groups from 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μg/knee, 6 patients in each group (7 patients in 10 μg) and single dose of ARG098 was intra-articularly administered to the target knee. Patients were required to be hospitalized at least 4 days after administration for close safety monitoring, and the assessment continued for 8 weeks with visit bases. <h3>Results</h3> The results showed that ARG098 was well-tolerated and no serious adverse events were observed. Total 33 adverse events (AEs) in 19 patients, and drug-related AEs in 9 patients which included non-clinical hepatological and cardiological findings were confirmed, however those were occurred in low frequency and the severity was all mild. ARG098 serum concentration was below the limit of qualification level (&lt;2.5 ng/mL). The clinical improvement was observed in most of the patients. Knee pain score by visual analogue scale (VAS) showed improvement at some assessment visits. The pain VAS of target knee was statistically improved at day 7 in 0.01 μg (-32.3±11.3 mm), day 14 and 28 in 1 μg (-27.3±19.3 mm, -27.5±19.6 mm) and day 7 and 14 in 10 μg (-37.4±26.0 mm, -35.4±26.0 mm) groups. The assessment with MRI showed improvement in more than half patients in 0.03 to 3 μg groups, and no deterioration was observed in all 43 patients. <h3>Conclusions</h3> The safety of single intra-articular administration of ARG098 was well-confirmed up to 10 μg/knee and the pain VAS assessment and MRI showed improvements. However the dose dependency was not clearly observed. Repeat administration of ARG098 Phase IIa placebo-controlled trial is ongoing to determine the appropriate dosage and assessment methods. <h3>Disclosure of Interest</h3> None Declared
Endoscopic removal of migrated esophageal stent - the “grasper and pusher” method
Authors: B. Martins, M. Sorbello, F. Retes, F. Kawaguti, M. Lima, F. Hondo, G. Stelko, U. Ribeiro, F. Maluf-Filho
Journal: Endoscopy (2012)

A 79-year-old man with metastatic adenocarcinoma of the cardia was submitted to palliative chemotherapy and esophageal stenting for relief of dysphagia. After the fourth cycle of chemotherapy he was admitted to the emergency department complaining of dysphagia. At endoscopy a significant regression of the lesion size and migration of the stent into the stomach were noticed. The standard gastroscope (9.8 mm) was easily inserted into the gastric chamber. In order to facilitate the use of the proximal lasso system to close the proximal end of the stent, the standard gastroscope was switched to the therapeutical scope, and a 10-Fr biliary stent pusher was inserted into the largest operational channel followed by a grasp forceps ([Fig. 1]). The lasso was grasped and pulled back into the pusher while the endoscopist's assistant advanced it against the stent. This maneuver allowed the constraining of the proximal end of the stent, facilitating its removal ([Fig. 2] and [Video 1]).
Early Commitment to Neoplasia in Murine B- and T-cell Lymphomas Arising Late in Life
Authors: N. V. Houten, P. B. Willoughby, L. W. Arnold, G. Haughton
Journal: JNCI Journal of the National Cancer Institute (1989)

Lymphomas arise spontaneously in C57BL/10.H-2aH-4b (2a4b) mice greater than 1 year old. The purpose of this study was to determine when cells become committed to neoplasia and whether genes linked to H-2a or H-4b are a factor in predisposition to genesis of lymphoma. Following transplantation of a pool of spleen cells in large groups of mice, lymphoma incidence increased 1.8- to 2.1-fold and mean latent periods decreased, compared with those in controls. Lymphomas arising in mice that received the same pool of spleen cells often displayed identical rearrangements of genes for immunoglobulin and T-cell receptor. This finding indicates that the lymphomas were derived from expanding clones of cells present in the donor mice prior to transfer. The age of the donor mice determined the latency of lymphomas arising after spleen cell transfer. When donors were 3-4 months old at the time of spleen cell transfer, lymphomas were detected in the recipients 1 year later. When mice 1.5-2 years old were used as donors, tumors were observed 3 months after transfer. Almost all of these tumors were clonally related B-cell lymphomas. We conclude that the lymphomas seen late in life arise from premalignant clones of cells that have become committed to neoplasia in relatively young animals. These clones normally follow an indolent course and are manifested clinically only in old age. Neither H-2a nor H-4b alone appeared to alter susceptibility to the genesis of lymphoma in similar experiments with H-2a and H-4b congenic mice.
S86 Effects of exposure to IL-13, IL-31 and an IL-13/31 combination on mucociliary differentiation of bronchial epithelial cells from normal children
Authors: J. C. Parker, S. T. Thavagnanam, G. Skibinski, L. G. Heaney, M. D. Shields
Journal: Thorax (2010)

<h3>Background</h3> Asthma is characterised by airway remodelling which includes smooth muscle hypertrophy, goblet cell hyperplasia and subsequent mucus hyper-secretion. Th2 cytokines including IL-13 and more recently IL-31 have been implicated in the pathogenesis of asthma. <h3>Objectives</h3> We aimed to examine the effects of IL-13 (20 ng/ml), IL-31 (20 ng/ml) and an IL-13/31 combination (20 ng/ml of both) on the in vitro mucociliary differentiation of paediatric bronchial epithelial cells (PBECs) from normal patients. <h3>Hypothesis</h3> We hypothesised that cells from normal children exposed to IL-13, IL-31 or an IL-13/31 combination would alter their phenotype towards that of an asthmatic epithelium. <h3>Methods</h3> Markers of differentiation, real time PCR for MUC5AC, MUC5AC ELISA and transepithelial electrical resistance (TEER) were assessed. <h3>Results</h3> We found that well-differentiated paediatric bronchial epithelial cells highly expressed the IL-31 receptor (IL-31RA). Transepithelial electrical resistance (TEER) indicated good formation of tight junctions which was found to be similar across all treatment groups. We found that IL-13 stimulation reduced the number of ciliated cells compared with control (IL-13 stimulation: mean=4.8% (SD=2.5); Control: mean=18.1%, (SD=5.9)). We did not find that the combination of IL-13 and IL-31 had any additional effects to that of IL-13 alone (IL-13/31 combination stimulation: mean=5.1% (SD=4.6); Control: mean=18.1%, (SD=5.9)). Stimulation with IL-13, IL-31 and the IL-13/IL-31 combination did not result in any changes of goblet cell numbers. <h3>Conclusions</h3> IL-31RA receptor is present in abundance in well-differentiated paediatric bronchial epithelial cells however IL-31 does not exhibit any detrimental effects on mucociliary differentiation or proliferation. In addition, IL-31 does not appear to have a synergistic effect when combined in culture with IL-13, in the differentiation process.
EXPERIENCIA INICIAL DE LA COLANGIO-PANCREATOGRAFÍA GUIADA POR ECOENDOSCOPIA (CPES): ESTUDIO MULTICÉNTRICO NACIONAL
Authors: JJ Vila, E Vázquez-Sequeiros, A Pérez Millán, F González-Huix, J Iglesias, JR Aparicio, JC Subtil, C De la Serna, F De la Morena, J García Cano, M Casi, A Barturen, SJ Rodríguez Gómez, A Repiso, A Lancho, D Juzgado, F Igea, I Fernández-Urién, JA González-Martín, M Pérez-Miranda
Journal: Endoscopy (2010)

Objetivos: Valorar: 10. Resultados iniciales del drenaje biliar y pancreático transmural guiado por ecoendoscopia (CPES), identificando fases de la técnica con mayor riesgo de fracaso. 20. Influencia de factores del endoscopista y paciente en el resultado.
Colonoscope incarceration in an inguinal hernia: a complication of colonoscopy
Authors: Adnan Tas, Cem Oruç, Sehmus Olmez, Mustafa Şahan, Mustafa Uğur, Sedat Hakimoğlu, Mehmet Demir
Journal: Endoscopy (2015)

One of the rare complications of colonoscopy is incarceration of the colonoscope in an inguinal hernia [1] [2]. We present a case of incarceration of the colonoscope in a left-sided hernia, which required reduction of the hernia by surgical dissection of the hernial sac.
Any foreseeable growth in NHS will "feel like a cut" because of demographics and cost inflation, report says
Authors: N. Hawkes
Journal: BMJ (2012)

The NHS in England faces a decade of austerity, and a squeeze on spending is likely to last at least until 2021-2, concludes a new analysis commissioned by the Nuffield Trust and carried out by the Institute for Fiscal Studies.1

In spite of the relative protection given to health spending by the government, demographic changes and cost inflation mean that under almost any imaginable scenario the NHS budget will rise more slowly than the likely demand. The immediate challenge of making £15bn (€20bn; $24bn) to £20bn of savings in four years during this parliament—the tightest four year period of funding for the NHS in the past half century—will continue into the next four years.

“If NHS productivity does not increase sufficiently fast to bridge the gap between funding and demand pressures, then access to and quality of care is likely to deteriorate,” the report says. “Serious thought must …
P167 Pathological Confirmation Rate of Lung Cancer in England Using the NLCA Database
Authors: A Khakwani, AL Rich, LJ Tata, HA Powell, RA Stanley, DR Baldwin, RB Hubbard
Journal: Thorax (2012)

<h3>Introduction</h3> The majority of people with lung cancer should have pathological confirmation of their diagnosis. The National Lung Cancer Audit (NLCA) recommends that NHS trusts obtain pathology (histology or cytology) for 75% of their lung cancer patients, however this figure was arbitrarily chosen and the optimal pathological confirmation rate is unknown. <h3>The Aims</h3> of this study were to provide a simple means of benchmarking appropriate pathological confirmation rates by stratifying patients into groups, and whether obtaining pathology based on those groups is associated with a survival benefit. <h3>Methods</h3> Using the NLCA database, we calculated the proportion of patients with non-small cell and small cell lung cancer, first seen between 1st January 2004 and 31st December 2010, who had pathological confirmation of their diagnosis. Using bivariate analysis, we identified the features which were most strongly associated with having pathology. We stratified our cohort according to these features and developed 4 groups (Table 1) based on the percentage of pathology obtained by the majority of NHS trusts during the study period. <h3>Results</h3> We analysed data on 136,993 individuals. The median age at diagnosis was 72 years (<i>IQR 64–79 years</i>). Performance status (PS) and age were the features most strongly associated with having a pathological diagnosis. Pathological confirmation was associated with a survival benefit at 6 months for patients in groups 1–3 and at 1 year for patients in group 1 &amp; 2 having adjusted for confounders (HR 0.93 &amp; 0.89 respectively). This survival benefit was removed when adjusted for treatment with chemotherapy (Table 2). <h3>Discussion</h3> Stratifying by age and PS, is a simple means of benchmarking pathological confirmation rates which is more appropriate than current recommendations. We have shown better survival at six months and one year for patients who had pathological confirmation of lung cancer in groups 1 and 2 (younger patients with better PS), even after adjusting for confounders. Much of this survival advantage was accounted for by adjusting for the use of chemotherapy. We would suggest, therefore, that clinicians should aim to achieve a pathologically confirmed diagnosis in every patient in groups 1 &amp; 2.
IMPACT OF CLOSURE DEVICES IN TAVI PROCEDURES ON VASCULAR COMPLICATIONS AND MORTALITY
Authors: Zisis Dimitriadis, Werner Scholtz, Marcus Wiemer, Cornelia Piper, Marios Vlachojannis, Stephan Ensminger, Thomas Bitter, Lothar Faber, Dieter Horstkotte, Smita Scholtz
Journal: Journal of the American College of Cardiology (2016)
Demonstration of Double-Chambered Right Ventricle on Myocardial Perfusion SPECT
Authors: NORIYUKI SHUKE, KENJI SUGIKI, HIROSHI AJIKI, HITOSHI HONMA, NAOYA YOSHIDA, TAMIO ABURANO, TAKEMI OHNO
Journal: Clinical Nuclear Medicine (1998)

A 19-year-old man with a double-chambered right ventricle (DCRV) and an associated ventricular septal defect was admitted to the hospital for surgical correction. Preoperative study of myocardial perfusion with Tc-99m tetrofosmin SPECT depicted the two chambers of the right ventricle. There was a substantial differential in the radioactive uptake between these two chambers. The inflow and outflow chambers with different peak-pressures (94 and 18 mm Hg) showed different uptakes reflecting the pressure difference, which was intense in the inflow chamber and weak in the outflow.
South Carolina Hosts Eighth International Cancer Symposium
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article South Carolina Hosts Eighth International Cancer Symposium Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 21, 4 November 1992, Page 1623, https://doi.org/10.1093/jnci/84.21.1623 Published: 04 November 1992
CLINICAL DECISION MAKING FOR THE HEMODYNAMIC GRAY ZONE (FFR 0.75-0.80) AND IMPACT ON LONG TERM OUTCOMES
Authors: Shiv Kumar Agarwal, Mohan Edupuganti, Ahmed Almomani, Naga Venkata Pothineni, Jason Payne, Srikanth Kasula, Sameer Raina, Fnu Shailesh, Barry Uretsky, Abdul Hakeem
Journal: Journal of the American College of Cardiology (2016)
Ki-ras Mutations in Pancreatic Secretions and Aspirates From Two Patients Without Pancreatic Cancer
Authors: H. Suzuki, S. Yoshida, Y. Ichikawa, H. Yokota, H. Mutoh, A. Koyama, M. Fukazawa, T. Todoroki, K. Fukao, K. Uchida, M. Miwa
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Ki-ras Mutations in Pancreatic Secretions and Aspirates From Two Patients Without Pancreatic Cancer Get access Hiromichi Suzuki, Hiromichi Suzuki Department of Biochemistiy, Institute of Basic Medical Sciences University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Sadao Yoshida, Sadao Yoshida Department of Biochemistiy, Institute of Basic Medical Sciences University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Yoshihito Ichikawa, Yoshihito Ichikawa Department of Biochemistiy, Institute of Basic Medical Sciences University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Hikaru Yokota, Hikaru Yokota Department of Internal Medicine, Institute of Clinical Medicine University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Hiroshi Mutoh, Hiroshi Mutoh Department of Internal Medicine, Institute of Clinical Medicine University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Akio Koyama, Akio Koyama Department of Internal Medicine, Institute of Clinical Medicine University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Masakatsu Fukazawa, Masakatsu Fukazawa Department of Pathology, Tsukuba University Hospital University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Takeshi Todoroki, Takeshi Todoroki Department of Surgery, Institute of Clinical Medicine University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Katashi Fukao, Katashi Fukao Department of Surgery, Institute of Clinical Medicine University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Kazuhiko Uchida, Kazuhiko Uchida Department of Biochemistiy, Institute of Basic Medical Sciences University of TsukubaIbaraki, Japan Correspondence to: Kazuhiko Uchida, M.D., Department of Biochemistry, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Ibaraki 305, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar ... Show more Masanao Miwa Masanao Miwa Department of Biochemistiy, Institute of Basic Medical Sciences University of TsukubaIbaraki, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 20, 19 October 1994, Pages 1547–1549, https://doi.org/10.1093/jnci/86.20.1547 Published: 19 October 1994 Article history Received: 26 April 1994 Revision received: 22 July 1994 Accepted: 09 August 1994 Published: 19 October 1994
STATIN USE AND TITRATION PATTERNS IN THE YEAR FOLLOWING A TYPE II DIABETES MELLITUS DIAGNOSIS IN MEDICARE BENEFICIARIES
Authors: Katherine Mues, Yi Peng, Suying Li, Jill Hardin, Deborah Kim, Anne Beaubrun, Keri Monda, Paul Muntner, Robert Rosenson, Charles Herzog
Journal: Journal of the American College of Cardiology (2016)
Colchicine in the Treatment of Cirrhosis of the Liver
Authors: David Kershenobich, Florencia Vargas, Guadalupe Garcia-Tsao, Ruy Perez Tamayo, Michael Gent, Marcos Rojkind
Journal: New England Journal of Medicine (1988)

There is preliminary evidence that colchicine, an inhibitor of collagen synthesis, may be beneficial in the treatment of cirrhosis of the liver. To evaluate the use of colchicine (1 mg per day, five days per week) in the treatment of hepatic cirrhosis, we performed a randomized, double-blind, placebo-controlled trial in which 100 patients were followed for up to 14 years. forty-five patients had alcoholic cirrhosis, 41 had posthepatitic cirrhosis, and the remaining 14 had cirrhosis with various other causes. Histologic studies were available for 92 percent of patients. Seventy-three patients were in Child–Turcotte class A, 26 were in class B, and one was in class C. Fifty-four patients received colchicine, and 46 received placebo. The overall survival in the colchicine group was markedly better than in the placebo group (median survival, 11 and 3.5 years, respectively; P<0.001). The cumulative 5-year survival rates were 75 percent in the colchicine group and 34 percent in the placebo group; the corresponding 10-year survival rates were 56 percent and 20 percent. Among the 30 patients treated with colchicine who underwent repeated liver biopsies, histologic improvement was seen in 9; the liver appeared normal in 2, and 7 had minimal portal fibrosis. No histologic improvement was observed in the 14 members of the placebo group who had two or more biopsies. Few side effects were observed in either group. (N Engl J Med 1988; 318:1709–13.)
MANGANESE CHELATE-ENHANCED MAGNETIC RESONANCE IMAGING OF MYOCARDIAL INFARCTION IN A RABBIT ISCHEMIA MODEL: COMPARISON WITH GADOLINIUM-ENHANCED MAGNETIC RESONANCE IMAGING
Authors: Lingyi Wen, Zhigang Yang, Chunchao Xia, Lizhi Zhang, Hua Ai, Yingkun Guo
Journal: Journal of the American College of Cardiology (2016)
SP0090 Similarities and Differences in RA Treatment Guidelines: the US View
Authors: K. Saag
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Under the aegis of its Quality of Care Committee, the American College of Rheumatology (ACR) is a periodically commissions the development of RA Treatment Guidelines. The last RA Treatment Guideline update was published in 2012 and a fully revised RA Treatment Guideline is under current development. In the past, the ACR has recommended the use of the RAND/UCLA appropriateness method. Currently, the methods being used is GRADE. Both methods require a formal literature synthesis. Differences in guidelines resulting from the two processes will be discussed. ACR RA Treatment Guidelines continue to focus on recommendations for the use of both biologic and non-biologic DMARDs based on therapeutic efficacy and safety considerations. New ACR RA guidelines will also consider the role of glucocorticiods in RA management. <h3>Disclosure of Interest</h3> K. Saag Consultant for: Abbott, Amgen, Crescendo, Novartis, Roche, <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6303
RESULTADOS Y APRENDIZAJE EN UN CURSO PRÁCTICO DE ECOENDOSCOPIA TERAPÉUTICA EN MODELO ANIMAL PORCINO
Authors: Á Terán Lantarón, B Castro Senosiain, P Iruzubieta Coz, G De Las Heras Castaño, JC Manuel-Palazuelos, JB Gornals Soler, JJ Vila Costa, M Pérez-Miranda, J De La Peña García
Journal: Endoscopy (2013)

Introducción: La terapéutica guiada por ultrasonografía endoscópica (TG-USE) está experimentando un amplio desarrollo en los últimos años, aunque no existen datos claros acerca de su curva de aprendizaje ni sobre el beneficio que puede suponer el entrenamiento con modelos animales. Objetivo: Estudio de la dificultad de diferentes TG-USEs y estimación del beneficio del entrenamiento en modelo animal. Material y Método: Análisis prospectivo de los datos recogidos en un curso práctico de entrenamiento en modelo animal porcino vivo con obstrucción biliar mediante clip OTSC® y dirigido a endoscopistas con experiencia previa en USE-PAAF y CPRE. Se entrenaron cuatro TG-USEs: drenaje de vía biliar principal (DVBP), colecisto-gastrostomía (CGS), drenaje transrectal de vejiga urinaria (DTVU) y gastro-yeyunostomía (GYS). Resultados: Se analizaron 33 procedimientos (11 DBVP, 5 CGS, 7 DTVU, 10 GYS) realizados por 12 endoscopistas en 10 animales (2,83 ± 0,58 procedimientos/endoscopista; 3,3 ± 1,42 procedimientos/animal). En la Tabla 1 se detallan los principales Resultados: DTVU+GYS fueron los más frecuentemente completados y finalizados con éxito, frente a DVBP+CGS (100% vs. 62,5%, p = 0,007; 82,4% vs. 37,5%, p = 0,011). El manejo de guía (35%), cistotomo (26,7%) y stent (25%) fueron los pasos que más frecuentemente supusieron problemas. Se apreciaron mejores resultados en los procedimientos realizados por cada participante en segundo y tercer lugar frente al primero, sin alcanzar la significación estadística, excepto la necesidad de ayuda del instructor (5% vs. 41,7%, p = 0,018).